Growth Metrics

Scholar Rock Holding (SRRK) Liabilities and Shareholders Equity (2017 - 2026)

Scholar Rock Holding's quarterly Liabilities and Shareholders Equity came in at $535.3 million in Q1 2026, up 31.33% year-on-year from $407.6 million in Q1 2025, and up 32.4% quarter-over-quarter from $404.3 million in Q4 2025.

Scholar Rock Holding has reported Liabilities and Shareholders Equity for 10 years, with the latest figure at $535.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 31.33% year-over-year to $535.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (up 31.26% YoY), and the FY2025 full-year result was $404.3 million, down 14.88% from the prior year.
  • Liabilities and Shareholders Equity for Q1 2026 stood at $535.3 million, up from $404.3 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $535.3 million in Q1 2026, with the low at $179.1 million in Q3 2024.
  • Average Liabilities and Shareholders Equity over 5 years is $343.9 million, with a median of $340.0 million recorded in 2025.
  • Year-over-year, Liabilities and Shareholders Equity tumbled 35.77% in 2023 and jumped 129.84% in 2025.
  • Tracing SRRK's Liabilities and Shareholders Equity over 5 years: stood at $358.2 million in 2022, then dropped by 13.16% to $311.0 million in 2023, then surged by 52.69% to $474.9 million in 2024, then dropped by 14.88% to $404.3 million in 2025, then soared by 32.4% to $535.3 million in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $535.3 million (Q1 2026), $404.3 million (Q4 2025), and $411.7 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 14.93 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 37.37 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 1.73 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 78.88 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 33.89 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 26.48 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - 23.64 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 40.87 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 5.13 Bn
10 Scholar Rock Holding 500.61 Mn 20.67 Mn - 535.25 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 535.25 Mn
Dec 31, 2025 404.27 Mn
Sep 30, 2025 411.72 Mn
Jun 30, 2025 340.05 Mn
Mar 31, 2025 407.55 Mn
Dec 31, 2024 474.92 Mn
Sep 30, 2024 179.13 Mn
Jun 30, 2024 226.87 Mn
Mar 31, 2024 267.29 Mn
Dec 31, 2023 311.04 Mn
Sep 30, 2023 250.69 Mn
Jun 30, 2023 284.90 Mn
Mar 31, 2023 314.72 Mn
Dec 31, 2022 358.17 Mn
Sep 30, 2022 390.30 Mn
Jun 30, 2022 424.13 Mn
Mar 31, 2022 265.98 Mn
Dec 31, 2021 304.45 Mn
Sep 30, 2021 298.39 Mn
Jun 30, 2021 332.05 Mn
Mar 31, 2021 360.59 Mn
Dec 31, 2020 388.31 Mn
Sep 30, 2020 163.42 Mn
Jun 30, 2020 156.36 Mn
Mar 31, 2020 175.70 Mn
Dec 31, 2019 196.38 Mn
Sep 30, 2019 188.54 Mn
Jun 30, 2019 196.91 Mn
Mar 31, 2019 170.98 Mn
Dec 31, 2018 181.34 Mn
Sep 30, 2018 109.02 Mn
Jun 30, 2018 118.98 Mn
Dec 31, 2017 61.64 Mn